Ox­ford Bio­med­ica sees new in­vest­ment for man­u­fac­tur­ing; Twist gets a part­ner to help build out dis­cov­ery li­braries 

Ox­ford Bio­med­ica has land­ed some new cash.

The British gene and cell ther­a­py biotech an­nounced Wednes­day it has se­cured an in­vest­ment “just over” £50 mil­lion from the Serum In­sti­tute of In­dia’s in­vest­ment arm. Funds are ex­pect­ed to help Ox­ford Bio­med­ica build out its 84,000-square-foot man­u­fac­tur­ing fa­cil­i­ty and bring on­line sev­er­al in­de­pen­dent suites by mid-2023.

“Serum In­sti­tute of In­dia has played a big part in the fight against COVID-19, as have we, and we look for­ward to a strong and col­lab­o­ra­tive re­la­tion­ship,” CEO John Daw­son said in a state­ment. “This in­vest­ment will al­low us to ex­pand ca­pac­i­ty at Oxbox at a time when our busi­ness de­vel­op­ment pipeline has nev­er looked stronger.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER